ACP’s New 2026 Obesity Medication Guidelines Explained

The management of chronic weight issues has entered a new era. Specifically, the American College of Physicians (ACP) recently published highly anticipated obesity medication guidelines to guide clinical decision-making. Consequently, physicians now possess a clear hierarchy for prescribing weight-management drugs alongside essential lifestyle modifications.

Applying the New Obesity Medication Guidelines

The ACP guidelines outline clear, evidence-based paths for adults with a body mass index (BMI) of 30 or higher. For these patients, clinicians should initiate first-line pharmacologic options alongside healthy lifestyle changes. First, semaglutide and tirzepatide represent the premier choices because of moderate-certainty clinical evidence. Alternatively, physicians can consider phentermine-topiramate as a second-line option, though it carries low-certainty evidence. Meanwhile, liraglutide serves as the third-line therapeutic selection, while naltrexone-bupropion occupies the fourth-line position. Clinicians must actively discuss potential side effects, patient preferences, and financial costs before writing a prescription.

Treating Overweight Patients with Comorbidities

In addition, the clinical guideline addresses nonpregnant adults with a BMI between 27 and 30 who suffer from weight-related comorbidities. These comorbidities include type 2 diabetes, dyslipidemia, hypertension, obstructive sleep apnea, and cardiovascular disease. For this population, semaglutide and tirzepatide remain the strongly recommended first-line therapies. In contrast, liraglutide serves as the designated second-line treatment option. However, clinicians must carefully review absolute contraindications and pregnancy risks before starting these medications. Ultimately, shared decision-making ensures that patients receive the safest and most effective therapy for their unique health profile.

Key Clinical Warnings and Contraindications

Safety remains a paramount concern when initiating these powerful weight-management drugs. For example, phentermine-topiramate requires patients to undergo monthly pregnancy tests due to severe teratogenic risks. Furthermore, physicians should never prescribe phentermine-topiramate to individuals with pre-existing cardiovascular disease. Similarly, naltrexone-bupropion carries an explicit warning regarding suicidal ideation, which demands close clinical monitoring. Consequently, doctors must discuss these potential harms thoroughly during every consultation. Therefore, aligning medication choices with the patient’s clinical history remains essential for minimizing adverse outcomes.

Frequently Asked Questions

Q1: Which medications serve as the first-line pharmacologic treatments according to the guidelines?

According to the guidelines, semaglutide and tirzepatide are the first-line pharmacologic choices for managing overweight and obesity when combined with lifestyle modifications.

Q2: What monitoring is required for patients taking phentermine-topiramate?

Patients taking phentermine-topiramate must undergo monthly pregnancy tests due to teratogenic risks. Additionally, physicians should avoid this drug in patients with cardiovascular disease.

Q3: How do the recommendations differ for adults with overweight versus obesity?

For adults with obesity (BMI ≥ 30), the guideline offers a four-tier drug hierarchy. In contrast, for overweight adults (BMI 27 to 30), the guideline only recommends pharmacotherapy if they have weight-related comorbidities like diabetes or hypertension.

References

1. Qaseem A et al. Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026). Ann Intern Med. 2026 Jun 16. doi: 10.7326/ANNALS-25-02714. PMID: 42296496.
2. Damen JAA et al. Benefits and harms of pharmacologic treatments in adults with overweight or obesity: a living systematic review and network meta-analysis for the American College of Physicians. Ann Intern Med. 2026 Jun 16. doi: 10.7326/ANNALS-24-03764.
3. Jenniskens K et al. Cost-effectiveness of pharmacologic treatments in adults with overweight or obesity: a systematic review for the American College of Physicians. Ann Intern Med. 2026 Jun 16. doi: 10.7326/ANNALS-24-03766.